Skip to main content

Table 1 Demographic and clinical information

From: Experiences, perspectives and priorities of people with schizophrenia spectrum disorders regarding sleep disturbance and its treatment: a qualitative study

 

n = (of 15)

Psychiatric diagnosis:

Schizophrenia

8

Schizoaffective disorder

6

Delusional disorder

1

Current level of support:

Independent accommodation, outpatient care

2

Independent accommodation, community team

8

Independent accommodation, daily support

2

Supported accommodation

1

Acute mental health ward

2

Psychotropic medications prescribed:

Hypnotics

1

Mood stabilisers

5

Anti-depressants

9

At least one antipsychotic

15

One antipsychotic

8

Two antipsychotics

7

Oral antipsychotics, no depota

11

Depot and oral antipsychotics

3

Depot antipsychotic, no oral antipsychotic

1

Clozapineb

2

Antipsychotic dosage (as a fraction of DDDc)

Range

0.36–5.5

Median / mean (SDd)

2 / 2.19 (1.28)

Gender:

% male

67%

Age:

Range

23–69 years

Median / mean (SD)

44 / 45.9 (10.55)

GAF-F score (functioning)e:

Range

38–85

Median / mean (SD)

65 / 62.3 (12.16)

GAF-S score (symptoms)e:

Range

21–80

Median / mean (SD)

39/ 47.7 (19.40)

  1. aLong-acting intramuscular injection, typically given every 1–4 weeks. bSpecified separately as only used in otherwise treatment resistant illness. cThe defined daily dose (DDD) is the assumed average maintenance dose per day for a drug used for its main indication in adults. [98] dStandard Deviation. eScores may range from 1 to 100, lower scores = more impairment